Viral oncology’s complicated path—from cancer as contagion to today’s immunotherapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In the late 1960s, NCI received the modern-day equivalent of billions of dollars to establish a viral oncology program.  At the time, the study of the role viruses played in cancer (or whether they played any role at all) was unknown.  This could have been either a triumph or a huge and embarrassing waste of...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Alexandria Carolan
Alexandria Carolan
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

Data from the IMROZ phase III trial demonstrated Sarclisa (isatuximab), in combination with standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd) followed by Sarclisa-Rd (the IMROZ regimen), significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with newly-diagnosed multiple myeloma not eligible for transplant. 
Alexandria Carolan
Alexandria Carolan
Reporter

Login